Sara Kenkare-Mitra

Strategic Advisor @Rani Therapeutics

South San Francisco, CA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Apr 2026 — Present

Strategic Advisor @Rani Therapeutics

View department →

EDUCATION

N/A

The University of Texas at Austin

Graduate Student,, Pharmaceutics

N/A

University of California, San Francisco - School of Medicine

Post doctoral Fellow, Clinical Pharmacology

1984 — 1988

The Bombay college of Pharmacy

B Pharm, Pharmacy

N/A

University of California, San Francisco

PhD, Biopharmaceutical sciences

SKILLS

BiotechnologyDrug DevelopmentOncologyDrug DiscoveryLifesciencesPharmaceutical IndustryPharmacologyClinical DevelopmentCancerNeurologyToxicologyClinical PharmacologyR&DIn VivoAssay DevelopmentClinical Research

ABOUT SARA KENKARE-MITRA

Dr. Sara Kenkare-Mitra is a seasoned biotech/pharma drug developer,scientist and executive, has served as the President and Head of R&D at Alector for the last four years. With over 25 years of industry experience, she has dedicated her career to developing novel drugs and personalizing treatments. Her work spans the entire drug discovery and development spectrum, including the successful global filing and launch of multiple drugs during her 24-year tenure at Genentech/Roche. While she has a particular focus on Oncology, she has also worked in areas such as neurodegeneration, ophthalmology, and respiratory diseases. She also serves on the Board of directors at Unicycive therapeutics, a public biotech company that is focused on therapies for patients with kidney diseases. Dr. Kenkare-Mitra and her organizations have contributed to the filing of 11 BLA/NDA for novel drugs currently on the market, including Xolair, Tarceva, Avastin, Lucentis, Kadcyla, Venclexta, Vismodegib, Perjeta, Tecentriq, Ocrevus, and Polivy, as well as over 100 IND/CTA submissions for novel NMEs. She has also enabled the successful development and approval of more than 15 companion diagnostics and several novel diagnostic technologies at Genentech/Roche. She was instrumental in driving the early success of the antibody-drug conjugate platform at Genentech and was part of the team that led to the discovery of Kadcyla. Additionally, her team has been integral in driving collaborations and strategic partnerships, such as the one with Foundation Medicine.Sara’s leadership and contributions to the field have earned her numerous accolades and memberships, including being elected a National Academy of Medicine (NAM) member and an fellow. She has also received awards for her leadership and influence from the San Francisco Business Times, Fierce Biotech, Endpoint News, AAPS, and has been celebrated as both a distinguished and Top 150 alumni at UCSF.Beyond her industry work, Dr. Kenkare-Mitra is an Adjunct Full Professor at UCSF and Adjunct faculty at the University of Pacific. She has served on the board of several non-profit organizations, including AWIS and the Genentech Foundation, and co-founded two successful mentoring programs at Genentech. Her academic qualifications include a PhD in Pharmaceutical Chemistry from UCSF, a Fellowship in Clinical Pharmacology UCSF, and post-doctoral training at UCSF.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.